GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Questcor Pharmaceuticals Inc (FRA:QPH) » Definitions » Total Long-Term Liabilities

Questcor Pharmaceuticals (FRA:QPH) Total Long-Term Liabilities : €111.8 Mil (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Questcor Pharmaceuticals Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Questcor Pharmaceuticals's Total Long-Term Liabilities for the quarter that ended in Jun. 2014 was €111.8 Mil.


Questcor Pharmaceuticals Total Long-Term Liabilities Historical Data

The historical data trend for Questcor Pharmaceuticals's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Questcor Pharmaceuticals Total Long-Term Liabilities Chart

Questcor Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.27 0.20 0.15 128.35

Questcor Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.48 127.58 128.35 124.03 111.85

Questcor Pharmaceuticals Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Questcor Pharmaceuticals Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Questcor Pharmaceuticals's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Questcor Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Questcor Pharmaceuticals Headlines

No Headlines